Raj Nagaraja
Overview
Explore the profile of Raj Nagaraja including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Konteatis Z, Travins J, Gross S, Marjon K, Barnett A, Mandley E, et al.
J Med Chem
. 2021 Apr;
64(8):4430-4449.
PMID: 33829783
The metabolic enzyme methionine adenosyltransferase 2A (MAT2A) was recently implicated as a synthetic lethal target in cancers with deletion of the methylthioadenosine phosphorylase () gene, which is adjacent to the...
2.
Kalev P, Hyer M, Gross S, Konteatis Z, Chen C, Fletcher M, et al.
Cancer Cell
. 2021 Jan;
39(2):209-224.e11.
PMID: 33450196
The methylthioadenosine phosphorylase (MTAP) gene is located adjacent to the cyclin-dependent kinase inhibitor 2A (CDKN2A) tumor-suppressor gene and is co-deleted with CDKN2A in approximately 15% of all cancers. This co-deletion...
3.
Fan B, Dai D, Cohen M, Xu H, Yin F, Nagaraja R, et al.
Clin Pharmacol Drug Dev
. 2020 Jul;
10(1):99-109.
PMID: 32648303
Ivosidenib, a small-molecule inhibitor of mutant isocitrate dehydrogenase 1, is primarily cleared by hepatic metabolism. This open-label study investigated the impact of hepatic impairment on ivosidenib pharmacokinetics (ClinicalTrials.gov: NCT03282513). Otherwise...
4.
Nagaraja R, Olaharski A, Narayanaswamy R, Mahoney C, Pirman D, Gross S, et al.
Toxicol Appl Pharmacol
. 2020 Jun;
401:115103.
PMID: 32522582
Small cell lung cancer (SCLC) is a particularly aggressive subset of lung cancer, and identification of new therapeutic options is of significant interest. We recently reported that SCLC cell lines...
5.
Konteatis Z, Artin E, Nicolay B, Straley K, Padyana A, Jin L, et al.
ACS Med Chem Lett
. 2020 Feb;
11(2):101-107.
PMID: 32071674
Inhibitors of mutant isocitrate dehydrogenase (mIDH) 1 and 2 cancer-associated enzymes prevent the accumulation of the oncometabolite d-2-hydroxyglutarate (2-HG) and are under clinical investigation for the treatment of several cancers...
6.
McKenney A, Lau A, Hanasoge Somasundara A, Spitzer B, Intlekofer A, Ahn J, et al.
J Clin Invest
. 2018 Sep;
128(10):4743.
PMID: 30222137
No abstract available.
7.
McKenney A, Lau A, Hanasoge Somasundara A, Spitzer B, Intlekofer A, Ahn J, et al.
J Clin Invest
. 2018 Jan;
128(2):789-804.
PMID: 29355841
Patients with myeloproliferative neoplasms (MPNs) frequently progress to bone marrow failure or acute myeloid leukemia (AML), and mutations in epigenetic regulators such as the metabolic enzyme isocitrate dehydrogenase (IDH) are...
8.
Yen K, Travins J, Wang F, David M, Artin E, Straley K, et al.
Cancer Discov
. 2017 Feb;
7(5):478-493.
PMID: 28193778
Somatic gain-of-function mutations in isocitrate dehydrogenases () 1 and 2 are found in multiple hematologic and solid tumors, leading to accumulation of the oncometabolite ()-2-hydroxyglutarate (2HG). 2HG competitively inhibits α-ketoglutarate-dependent...
9.
Moss N, Xiong Z, Burke M, Cogan D, Gao D, Haverty K, et al.
Bioorg Med Chem Lett
. 2012 Oct;
22(23):7189-93.
PMID: 23084902
This paper details exploration of a class of triazole-based cathepsin S inhibitors originally reported by Ellman and co-workers. SAR studies involving modifications across the whole inhibitor provide a perspective on...
10.
Moss N, Choi Y, Cogan D, Flegg A, Kahrs A, Loke P, et al.
Bioorg Med Chem Lett
. 2009 Mar;
19(8):2206-10.
PMID: 19307114
We have been exploring the potential of 5-HT(2B) antagonists as a therapy for chronic heart failure. To assess the potential of this therapeutic approach, we sought compounds possessing the following...